氩氦刀冷冻消融挽救治疗胃癌肝转移患者

摘要

Objective To evaluate the curative effect and safety of percutaneous argon-helium knife cryoablation in treating patients with liver metastases from gastric cancer.Methods The clinical data of 24 patients with liver metastases from gastric cancer,who had received percutaneous argon-helium knife cryoablation therapy,were retrospectively analyzed.A total of 33 metastatic lesions could be used for evaluation.CT-guided percutaneous argon-helium knife cryoablation of liver metastases was carried out in all patients.The 3-month,6-month and 12-month local control rate,overall survival (OS) rate,progression -free survival (PFS),incidence of recurrence,preoperative and postoperative quality of life,and complications were documented.Results The median follow-up time was 14 months (6-48 months).After cryoablation therapy,the quality of life was improved significantly.The 3-month,6-month and 12-mouth local control rates were 91.7％,73.9％ and 52.6％ respectively.Mter cryoablation therapy,the median PFS was 8 months (1-16 months),the median survival time was 16 months,and the one-year and 2-year survival rates were 75.0％ and 37.5％ respectively.No severe complications occurred.Conclusion For the treatment of liver metastases from gastric cancer,percutaneous argon-helium knife cuoablation is safe and effective with reliable short-term curative effect,the patient's quality of life can be well improved.%目的 探讨氩氦刀冷冻消融挽救治疗胃癌肝转移患者的疗效及安全性.方法 回顾分析接受氩氦刀冷冻消融的24例胃癌肝转移患者的临床资料,其中33个可评价病灶.所有患者行CT引导下经皮穿刺肝转移瘤冷冻治疗,研究内容包括术后3个月、6个月及1年的肿瘤局部控制率,总生存率,疾病无进展生存时间,病灶的复发情况,术前术后患者生活质量变化情况及并发症.结果 患者中位随访时间为14(6～48)个月.冷冻消融术后患者生活质量明显提高,术后3个月、6个月及1年的病灶局部控制率分别为91.7％,73.9％,52.6％.经过冷冻消融治疗后,中位疾病无进展生存期为8(1～16)个月,患者中位生存时间为16个月,1年及2年生存率为75.0％及37.5％,未见严重并发症.结论 氩氦刀冷冻消融治疗胃癌肝转移,安全有效,近期疗效确切,可提高患者生活质量.